Sarcosine-based glycine transporter type-1 (GlyT-1) inhibitors containing pyridazine moiety: A further search for drugs with potential to influence schizophrenia negative symptoms

Current Pharmaceutical Design

Volumn 21, Issue 17, 2015, Pages 2291-2303

  Harsing, Laszlo G ^a   Timar, Julia ^a   Szabo, Geza ^b   Udvari, Szabolcs ^b   Nagy, Katalin M ^b   Marko, Bernadett ^b   Zsilla, Gabriella ^c   Czompa, Andrea ^a   Tapolcsanyi, Pal ^a   Kocsis, Akos ^a   Matyus, Peter ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b EGIS PHARMACEUTICALS LTD   (Hungary)

^c INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Glycine; Glycine transporter 1 inhibitors; Glycine transporters; Sarcosine; Sarcosine based pyridazine containing glycine transporter 1 inhibitors; Sarcosine containing glycine transporter 1 inhibitors

Indexed keywords

1 [3 CHLORO 1 (4 FLUOROPHENYL)PROPOXY] 4 PHENOXYBENZENE; 2 [[3 (4 FLUOROPHENYL) 3 HYDROXYPROPYL](METHYL)AMINO] N,N DIMETHYLACETAMIDE; 2 [[3 (4 FLUOROPHENYL) 3 [4 (1 METHYL 6 OXO 1,6 DIHYDROPYRIDAZIN 4 YLOXY)PHENOXY]PROPYL(METHYL)AMINO]N,N DIMETHYLACETAMIDE; 3 (4 FLUOROPHENYL) N METHYL 3 (4 PHENOXYPHENOXY)PROPAN1 AMINE; 4 [[3 (BIPHENYL 4 YLOXY) 3 (4 FLUOROPHENYL)PROPYL](METHYL)AMINO] 2 METHYLPYRIDAZIN 3(2H)ONE; 4 [[3 (BIPHENYL 4 YLOXY) 3 (4 FLUOROPHENYL)PROPYL](METHYL)AMINO]PYRIDAZIN 3(2H)ONE; ETHYL [3 (4 FLUOROPHENYL) 3 [4 (1 METHYL 6 OXO 1,6 DIHYDROPYRIDAZIN 4 YLOXY)PHENOXY]PROPYL](METHY)AMINOACETATE; ETHYL [3 (4 FLUOROPHENYL) 3 [4 (6 OXO 1,6 DIHYDROPYRIDAZIN 4 YLOXY)PHENOXY]PROPYL](METHY)AMINOACETATE; ETHYL([3 (4 FLUOROPHENYL) 3 [6 OXO 1 (3 TRIFLUOROMETHYLPHENYL) 1,6 DIHYDROPYRIDAZIN 4 YLOXY)PROPYL](METHYL)AMINO]ACETATE; ETHYL[[3 (4 FLUOROPHENYL) 3 (4 PHENOXYPHENOXY)PROPYL](METHYL)AMINO]ACETATE; ETHYL[[3 (4 FLUOROPHENYL) 3 (6 OXO 1 PHENYL1,6 DIHYDROPYRIDAZIN 4 YLOXY)PROPYL](METHYL)AMINO]ACETATE; IONOTROPIC RECEPTOR; LITHIUM ([3 (4 FLUOROPHENYL) 3 [4 (1 METHYL 6 OXO 1,6 DIHYDROPYRIDAZIN 4 YLOXY)PHENOXY]PROPYL](METHYL)AMINO)ACETATE MONOHYDRATE; LITHIUM ([3 (4 FLUOROPHENYL) 3 [4 (6 OXO 1 PHENYL 1,6 DIHYDROPYRIDAZIN 4 YLOXY)PHENOXY]PROPYL](METHYL)AMINO)ACETATE MONOHYDRATE; LITHIUM ([3 (4 FLUOROPHENYL) 3 [4 (6 OXO 1,6 DIHYDROPYRIDAZIN 4 YLOXY)PHENOXY]PROPYL](METHYL)AMINO)ACETATE MONOHYDRATE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; PYRIDAZINE DERIVATIVE; SODIUM[[3 (4 FLUOROPHENYL) 3 (4 PHENOXYPHENOXY)PROPYL](METHYL)AMINO]ACETATE MONOHYDRATE; UNCLASSIFIED DRUG; [3 (4 FLUOROPHENYL) 3 [4 (1 METHYL 6 OXO 1,6 DIHYDROPYRIDAZIN 4 YLOXY)PHENOXY]PROPYL](METHYL)AMINOACETIC ACID DIHYDROCHLORIDE DIHYDRATE; [3 (4 FLUOROPHENYL) 3 [4 (1 METHYL 6 OXO 1,6 DIHYDROPYRIDAZIN 4 YLOXY)PHENOXY]PROPYL](METHYL)AMINOACETIC ACID MONOHYDROCHLORIDE MONOHYDRATE; [3 (4 FLUOROPHENYL) 3 [4 (1 METHYL 6 OXO 1,6 DIHYDROPYRIDAZIN 4 YLOXY)PHENOXY]PROPYL](METHYL)AMINO] N,N DIMETHYLACETAMIDE DIHYDROCHLORIDE; GLYCINE TRANSPORTER; PYRIDAZINE; SARCOSINE; SLC6A9 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHO CELL LINE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; LOCOMOTION; MALE; MITSUNOBU REACTION; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; STRUCTURE ACTIVITY RELATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; CRICETULUS; DOSE RESPONSE; DRUG DESIGN; INBRED MOUSE STRAIN; MOUSE; SYNTHESIS; WISTAR RAT;

ANIMALS; CHO CELLS; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; GLYCINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; MALE; MICE; MICE, INBRED STRAINS; MOLECULAR STRUCTURE; PYRIDAZINES; RATS; RATS, WISTAR; SARCOSINE; SCHIZOPHRENIA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84929492566     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612821666150109125623     Document Type: Article

References (57)

1. Vizi ES. Role of high-affinity receptors and membrane transporters in nonsynaptic communication and drug action in the central nervous system. Pharmacol Rev 2000; 53: 63-89.
2. Zafra F, Gimenez C. Glycine transporters and synaptic function. IUBMB Life 2008; 60: 810-7.
3. Danysz W, Parson CG. N-Methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol Rev 1998; 50: 597-664.
4. Zhou X, Ding, Q, Chen Z, Yun H, Wang H. Involvement of the GluN2A and GluN2B subunits in synaptic and extrasynaptic Nmethyl-D-aspartate receptor function and neuronal excitability. J Biol Chem 2013; 33: 24151-9.
5. Papouin T, Ladepeche L, Ruel J, et al. Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists. Cell 2012; 150: 633-46.
6. Harsing LG Jr, Matyus P. Mechanisms of glycine release, which build up synaptic and extrasynaptic glycine levels: the role of synaptic and non-synaptic glycine transporters. Brain Res Bull 2013; 93: 110-9.
7. Deutsch SI, Mastropaolo J, Schwartz BL, Rosse RB, Morihisa JM. A “glutamatergic hypothesis“ of schizophrenia. Clin Neuropharm 1989; 12: 1-13.
8. Javitt DC. Glycine transport inhibitors and the treatment of schizophrenia. Biol Psychiatry 2008; 63: 6-8.
9. Hersesco-Levy U, Javitt DC, Ermilov M, Mordel C, Horowitz A, Kelly D. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment resistant schizophrenia. Br J Psychiatry 1996; 169: 610-7.
10. Hersesco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 1999; 56: 29-36.
11. Heresco-Levy U, Ermilov M, Lichtenberg P, Bar G, Javitt DC. High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol Psychiatry 2004; 55: 165-71.
12. Johnson JW, Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 1987; 325: 529-31.
13. Umbricht D, Martin-Facklam M, Pizzagalli F. Glycine transporter type1 (GlyT1) inhibitor RG1678: results of the proof-of-concept study for the treatment of negative symptoms in schizophrenia. 28th CINP World Congr Neuropsychopharmacol 2012; S28.
14. D’Souza DC, Singh N, Elander J, et al. Glycine transporter inhibitor attenuates the psychotomimetic effects of ketamine in healthy males: preliminary evidence. Neuropsychopharmacology 2012; 37: 1036-46.
15. Herdon HJ, Godfrey FM, Brown AM, Coulton S, Evans JR, Cairns WJ. Pharmacological assessment of the role of glycine transporter GlyT-1 in mediating high affinity glycine uptake by rat cerebral cortex and cerebellum synaptosomes. Neuropharmacology 2001; 41: 88-96.
16. Brown A, Carlyle I, Clark J, et al. Discovery and SAR of Org 24598-a selective glycine uptake inhibitor. Bioorg Med Chem Lett 2001; 11: 2007-9.
17. Harsing LG Jr, Gacsalyi I, Schmidt E, et al. The glycine transporter 1 inhibitor NFPS and Org-24461: a pharmacological study. Pharmacol Biochem Behav 2003; 74: 811-25.
18. Kinney GC, Sur C, Burno N, et al. The glycine transporter type 1 inhibitor N-3-(4’-fluorophenyl)-3-(4’-phenylphenoxy)propyl]sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behaviour. J Neurosci 2003; 23: 7566-91.
19. Perry KW, Falcone JF, Fell MJ, et al. Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas. Neuropharmacology 2008; 55: 743-54.
20. Le Pen G, Kew J, Alberati D, Borroni E, Heitz MP, Moreau JL. Prepulse inhibition deficits of the startle reflex in neonatal ventral hippocampus-lesioned rats: reversal by glycine and a glycine transporter inhibitor. Biol Psychiatry 2003; 54: 1162-70.
21. Harsing LG Jr, Juranyi ZS, Tapolcsanyi P, Czompa A, Matyus P. Glycine transporter type-1 and its inhibitors. Curr Med Chem 2006; 13: 1017-44.
22. Lindsley CW, Wolkenberg SE, Kinney GG. Progress in the preparation and testing of glycine transporter type-1 (GlyT1) inhibitors. Curr Topics Med Chem 2006; 6: 1883-96.
23. Kopec K, Flood DG, Gasior M, et al. Glycine transporter (GlyT1) inhibitors with reduced residence time increase prepulse inhibition without inducing hyperlocomotion in DBA/2 mice. Biochem Pharmacol 2010; 80: 1407-17.
24. Hashimoto K. Glycine transporter inhibitors as therapeutic agents for schizophrenia. Recent Patents CNS Drug Discover 2006; 1: 43-53.
25. Harsing LG Jr. An overview to GlyT-1 inhibitors under evaluation for the treatment of schizophrenia. Drugs Future 2013; 38: 545-58.
26. Harvey RJ, Yee BK. Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain. Nature Reviews Drug Discovery 2013; 12: 866-85.
27. Matyus P, Harsing LG Jr, Tapolcsanyi P, et al. New glycine transporter inhibitors: design, synthesis and biological evaluation. 4th BBBB-Bled Internat Conf Pharmaceut Sci, Bled, Slowenia, Sept 28-Oct 1, 2011.
28. Szabo G, Szabo E, Egyed A, Harsing LG. In vivo effects of GlyT-1 inhibition on brain receptors and transporters. Eur Brain Winter Conf Brain Res Les Arcs 2005; Abstr 96.
29. Lowry OH, Rosenbrough N, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-75.
30. Nagy KM, Marko B, Zsilla G, et al. Alterations in brain extracellular dopamine and glycine levels following combined administration of the glycine transporter type-1 inhibitor Org-24461 and risperidone. Neurochem Res 2010; 35: 2096-106.
31. Rowley HL, Martin KF, Marsden CA. Determination of in vivo amino acid neurotransmitters by high performance liquid chromatography with o-phthaldialdehyde-sulphite derivatization. J Neurosci Methods 1995; 57: 93-9.
32. Atkinson BN, Bell SC, De Vivo M, et al. ALX-5107: a potent, selective inhibitor of the hGlyT1 glycine transporter. Mol Pharmacol 2001; 60: 1414-20.
33. Hashimoto K. Glycine transporter-1: a new potential therapeutic target for schizophrenia. Curr Pharmaceut Design 2011; 17: 112-20.
34. Perez-Siles G, Morreale A, Leo-Macias A, et al. Molecular basis of the differential interaction with lithium of glycine transporters GlyT1 and GlyT2. J Neurochem 2011; 118: 195-204.
35. Johnson KW, Clemens-Smith A, Nomikos G, et al. In vivo characterization of changes in glycine levels induced by GlyT1 inhibitors. Ann NY Acad Sci 2003; 1003: 412-14.
36. Drescher KU, Jongen-Relo AL, Behl B, Gross G, Schoemaker H. Comparison of the GlyT1 inhibitor Org-24461 with aripiprazole and risperidone in PCP-induced neurochemical and behavioral changes. Proc 11th Int Conf In Vivo Methods 2006; 456-58.
37. Lindsley CW, Zhao Z, Leister WH, et al. Design, synthesis, and in vivo efficacy of novel glycine transporter-1 (GlyT1) inhibitors derived from a series of 4-phenyl-1-(propyl-sulfonyl)-(piperidin-4-yl-methyl)benzamides. Chem Med Chem 2006; 1: 807-11.
38. Harsing LG Jr, Zsilla G, Matyus P, et al. Interactions between glycine transporter type 1 (GlyT-1) and some inhibitor molecules. Acta Physiol Hung 2012; 99: 1-17.
39. Toth E, Weiss B, Banay-Schwartz M, Lajtha A. Effect of glycine derivatives on behavioral changes induced by 3-mercaptoproprionic acid or phencyclidine in mice. Res Comm Psychol Psychiatr Behav 1986; 11: 1-9.
40. Hashimoto K. Glycine transporter inhibitors for the treatment of schizophrenia. Open Med Chem J 2010; 4: 10-9.
41. Wolkenberg SE, Sur C. Recent progress in the discovery of nonsarcosine based GlyT1 inhibitors. Curr Topics Med Chem 2010; 10: 170-86.
42. Mezler M, Hornberger W, Mueller R, et al. Inhibitors of GlyT1 affect glycine transport via discrete binding sites. Mol Pharmacol 2008; 74: 1705-15.
43. Morrow JA, Gilfillan R, Calpine CM, et al. Functional characterization of structurally distinct classes of glycine transporter type1 (GlyT1) inhibitors. Soc Neurosci, Washington, DC., USA, Nov 12-16, 2011; Abstr 236.04.
44. Alberati D, Moreau JL, Lengyel J, et al. Glycine reuptake inhibitor RG1678: a pharmacological characterization of an investigational agent for the treatment of schizophrenia. Neuropharmacology 2012; 62: 1152-61.
45. Pinard E, Alanine A, Alberati D, et al. Selective GlyT1 inhibitors: discovery of 4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl]5-methanesulfonyl-2((S)-2,2,2-trifluoro-1-methylethoxy)-phenyl]-methanone (RG 1678), a promising novel medicine to treat schizophrenia. J Med Chem 2010; 53: 4603-14.
46. Tamminga CA. Schizophrenia and glutamatergic transmission. Crit Rev Neurobiol 1998; 12: 21-36.
47. Javitt DC. Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification. Curr Opin Drug Discover Develop 2009; 12: 468-78.
48. Chue P. Glycine reuptake inhibition as a new therapeutic approach in schizophrenia: focus on the glycine transporter 1 (GlyT1). Curr Pharmaceut Design 2013; 19: 1311-20.
49. Balla A, Koneru R, Siley J, Sershen H, Javitt DC. Continuous phencyclidine treatment induces-schizophrenia-like hyperactivity of striatal dopamine release. Neuropsychopharmacology 2001; 25: 157-64.
50. Depoortere R, Dargazanli G, Estenne-Bouhtou G, et al. Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic. Neuropsychopharmacology 2005; 30: 1963-85.
51. Papp A, Juranyi Z, Nagymajtenyi L, Matyus P, Harsing LG Jr. The synaptic and nonsynaptic glycine transporter type-1 inhibitors Org-24461 and NFPS alter single neuron firing rate in the rat dorsal raphe nucleus. Further evidence for a glutamatergic-serotonergic interaction and its role in antipsychotic action. Neurochem Internat 2008; 52: 130-4.
52. Brickley SG, Misra C, Mok MH, Mishina M, Cull-Candy SG. NR2B and NR2D subunits coassemble in cerebellar Golgi cells to form a distinct NMDA receptor subtype restricted to extrasynaptic sites. J Neurosci 2003; 23: 4958-66.
53. Vizi ES, Buonanno A. Editorial. Brain Res Bull 2013; 93: 1-3.
54. ClinicalTrials.gov NCT01116830, Sponsor: Hoffman La Roche.
55. ClinicalTrials.gov NCT00725075, Sponsor: Schering-Plough.
56. Kingwell K. Schizophrenia drug gets negative results for negative symptoms. Nature Reviews Drug Discovery 2014; 13: 244-5.
57. Schoemaker JH, Jansen WT, Schipper J, Szegedi A. The selective glycine uptake inhibitor Org 25935 as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia. J Clin Psychopharmacol 2014; 34:190-8.